Hsbc Holdings PLC Takes $17.66 Million Position in DaVita Inc. $DVA

Hsbc Holdings PLC acquired a new position in DaVita Inc. (NYSE:DVA) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 79,500 shares of the company’s stock, valued at approximately $17,660,000.

A number of other hedge funds have also bought and sold shares of DVA. Fifth Third Bancorp lifted its holdings in DaVita by 831.4% during the 1st quarter. Fifth Third Bancorp now owns 38,411 shares of the company’s stock worth $5,903,000 after purchasing an additional 34,287 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in DaVita by 30.5% during the 2nd quarter. Assenagon Asset Management S.A. now owns 44,783 shares of the company’s stock valued at $9,963,000 after buying an additional 10,477 shares in the last quarter. SG Americas Securities LLC increased its position in shares of DaVita by 27.4% during the first quarter. SG Americas Securities LLC now owns 212,293 shares of the company’s stock valued at $32,627,000 after buying an additional 45,609 shares during the period. LSV Asset Management lifted its holdings in shares of DaVita by 1.1% in the fourth quarter. LSV Asset Management now owns 936,768 shares of the company’s stock worth $106,426,000 after buying an additional 9,739 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S lifted its holdings in shares of DaVita by 63.5% in the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 86,000 shares of the company’s stock worth $9,770,000 after buying an additional 33,394 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVA has been the subject of several recent analyst reports. Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. UBS Group boosted their price target on shares of DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research report on Friday, July 10th. Oppenheimer set a $220.00 price objective on DaVita in a research report on Friday, August 7th. Finally, Barclays boosted their target price on DaVita from $218.00 to $224.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $221.75.

Insider Transactions at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.90% of the stock is currently owned by company insiders.

DaVita Price Performance

DVA stock opened at $178.70 on Friday. The firm has a 50 day simple moving average of $212.49 and a two-hundred day simple moving average of $183.06. The stock has a market cap of $11.40 billion, a PE ratio of 14.62, a P/E/G ratio of 0.60 and a beta of 0.88. DaVita Inc. has a one year low of $101.00 and a one year high of $247.49.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. During the same period in the previous year, the firm posted $2.95 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, research analysts expect that DaVita Inc. will post 14.57 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.